Please complete the CAPTCHA to continue
@hai-solutions.com
✓
2 phones found area 734
✓
LinkedIn matched
A concise factual answer block for searchers comparing this professional profile.
Prasad Sunkara, Ph. D is listed as Managing Director, Seed to Fruit Fund at HAI Solutions, based in San Diego, California, United States. AeroLeads shows a work email signal at hai-solutions.com, phone signal with area code 734, and a matched LinkedIn profile for Prasad Sunkara, Ph. D.
Prasad Sunkara, Ph. D previously worked as Co Founder and Chief Executive Officer at Eyegenex, Inc., (Www.Eyegenex.Com) and Co Founder and Chairman at Peroral Biosciences, Inc.. Prasad Sunkara, Ph. D holds Post Doctoral Fellowship, Cell And Tumor Biology from The University Of Texas Md Anderson Cancer Center Uthealth Graduate School Of Biomedical Sciences.
This section adds company-level context without repeating Prasad Sunkara, Ph. D's masked contact details.
AeroLeads found 1 current-domain work email signal for Prasad Sunkara, Ph. D. Compare company email patterns before reaching out.
Dr. Sunkara is a seasoned CEO, accomplished scientist, serial entrepreneur and a successful investor. He helped in building several startup Life Science companies, hiring great talent leading to successful exits.He combines over 35 years of corporate, financing, research, development and management experience in cancer, cardiovascular, CNS disease indications, molecular diagnostics and devices at Marion Merrell Dow pharmaceuticals (now Sanofi Aventis) and twelve other start up biotech and Medical Device companies in California and Michigan. Dr. Sunkara is an expert in identifying and licensing compelling technologies from universities and accelerating their preclinical and clinical development on a virtual basis while minimizing costs. He also gained valuable experience in business development, financing as an officer in four and as a founder, CEO and Board member at nine other start-up biotech, diagnostic and device companies. He helped them to grow and exit with significant appreciation to shareholders. As Senior Managing Director of a Life Science focused investment bank, he also successfully assisted a number of health care companies with strategic advice , fund raising, mergers and acquisitions.Currently he is actively assisting a number of start up Biotech, Medical device and diagnostic companies as Life Sciences Committee member at NuFund Venture Group, active investor, Board member and advisor.He is the founder and Managing Director of Seed to Fruit LLC (STF), a startup studio and accelerator. Eyegenex, Inc., is the first startup established by STF to develop gene and peptide therapeutics for the treatment of glaucoma, a major unmet medical need in ophthalmology.Dr. Sunkara is an author of over 140 peer reviewed publications and an inventor of 35 patents.Specialties: Biotechnology, Medical Devices Diagnostics, CRO and therapeutics start up, management, research and development, financing and business development. Operations, P&L responsibility, Pharmaceutical, medical device and diagnostics virtual development, Cross border development in India and US. Investment, Mergers , Acquisitions and negotiating licensing deals with Biotech and Pharmaceutical companies. Angel investment, private equity and Venture Capital investment.
Listed skills include Biotechnology, Pharmaceutical Industry, Drug Discovery, Drug Development, and 46 others.
Company context helps verify the profile and gives searchers a useful next step.
A career timeline built from the work history available for this profile.
San Diego CA
Eyegenex,Inc is developing gene and peptide therapeutics for the treatment of Glaucoma and help in Preventing blindness.
San Diego, California, United States
La Jolla, California, United States
Seed to Fruit (STF) is a founding studio and an accelerator for new startups leveraging on University IP, providing early pre-seed funding and accelerating the initial product development under the guidance of exceptional Advisors consisting of physicians, scientists, biomedical engineers and Angel investors.Eyegenex, Inc, is the first portfolio company of.
California, United States
Startup Express multi-class LLCs enable accredited investors to expand and diversify their investments in smaller amounts and at a lower cost.
Carlsbad, California, United States
HAI Solutions is developing a unique portfolio of medical devices that addresses the growing plague of contamination within the Operating Room, Emergency Room, and Intensive Care Units. Our platform of innovative vascular access technology targets the prevention of Healthcare-Associated Infections like CLABSI, CRBSI, and SSI.
Carlsbad, California, United States
San Diego County, California, United States
San Diego, California
San Diego, CA
Assisting students and professors in successful formation of startup Life science companies as part of Office of Innovation and Commercialization at University of California at San Diego, CA.
Phoenix, Arizona
Paradigm was acquired by Exact Sciences on March 3, 2020.
Iowa City, Iowa Area
Rights for distribution of Halo device was acquired by Fresenius Kabi. Medical device Company developing Closed System Transfer Device for compounding cytotoxic anticancer and antiviral drugs.
Minneapolis, Minnesota
Medical Device company developing breakthrough technologies for surgical resection of prostate in Benign Prostatic Hypertrophy patients.
TMI focuses on conducting phase 2 proof of concept studies in oncology, gastroenterology and diabetes as per GCP regulations leveraging the talent, access to patient population and cost advantages in India.
Ann Arbor, MI
Developed strategy to transform the company into a Medical device and diagnostic company with multiple products. Raised needed capital and executed the business plan into obtaining regulatory approvals and consummated marketing deals in India and Middle East.
Ann Arbor, MI
Identified and licensed Angiodefender device. Assited in obtaining the CE mark for the device and merger with Everist Genomics.
Advising and managing development of strategy, fund raising and M&A assistance for Medical Device and biotech companies. The company has successfully completed a number of transactions in US, Europe, India and Middle East.
Assisted in Strategy, Research and Development as a Board member.
Part of a team that helped in completing acquisition of a US biotech company and Licensing of Clinical stage assets by a Swiss Pharma company worth $300 Millions.
Responsible for the overall administration, operation and strategic planning of this Ann Arbor, MI. based Biotech Company focusing on developing novel imaging and therapeutic agents for cancer and cardiovascular therapeutic areas based on proprietary drug delivery and molecular technology.I helped to transform the company into a holding company of three.
Co founded a CRO with unique capabilities of in vivo efficacy evaluation (in a number of therapeutic areas) combining with molecular imaging modalities such as MRI, CT, PET imaging technologies of pre clinical and clinical compounds. This company was acquired by Charles River Labs in 2008 for a significant ROI for share holders.
Execute the business model as a technology transfer company in licensing products and drug delivery technologies with phase 1 data in therapeutic area of cancer from universities and non-profit institutes. Identified a cancer technology and helped to form Novacea by working with Dr. Eckard Weber, a venture partner with Domain Associates. Responsible to.
Greater San Diego Area
Reporting to the CEO and as an officer of the company, I was responsible for the overall research, preclinical and clinical development of lead caspase inhibitors and inducer compounds discovered by Cytovia’s proprietary screening technology. I was responsible for developing the strategy, budget and execution of both research and development. I was part of.
Reporting to the CEO and as an officer of the company, I was responsible for the overall preclinical and clinical development of lead compounds acquired from collaborations with the Picower Institute of Medical Research. I was responsible for virtual development of all the preclinical aspects of drug development (cGMP manufacturing of drug substance and.
Reporting to the CEO, I am primarily responsible for preclinical and pharmaceutical development and filing of INDs with both the U.S. FDA and Canadian HPB for the initiation of clinical trials. During the past three years, I have developed expertise in conducting all the preclinical and pharmaceutical development efforts, such as analytical methods.
Responsible for the discovery and preclinical development of lead compounds in the therapeutic areas of cancer and virology.During my tenure at MMD, I built the tumor biology group from four people to a group of twenty-five scientists and lead the discovery and development team. I published about ninety papers in peer review journals and was an inventor of.
Conducted original research cell cycle regulation in tumor cells. Published 24 peer reviewed publications in prestigious journals. Awarded two R01 grants. One from NCI with perfect score (100) and the second one from American Cancer Society.
Activities and Societies: Conducted research on the regulation of cell cycle in mammalian cells at M.D.anderson Cancer center, Houston.
1976 Recipient of the "Young Scientist Award" from Indian National Science Academy presented by Mrs. Indira Gandhi, Prime Minister of.
Graduated First in the class.
Quick answers generated from the profile data available on this page.
Prasad Sunkara, Ph. D works for HAI Solutions.
Prasad Sunkara, Ph. D is listed as Managing Director, Seed to Fruit Fund at HAI Solutions.
AeroLeads has found 1 work email signal at @hai-solutions.com for Prasad Sunkara, Ph. D at HAI Solutions.
AeroLeads has found 2 phone signal(s) with area code 734 for Prasad Sunkara, Ph. D at HAI Solutions.
Prasad Sunkara, Ph. D is based in San Diego, California, United States while working with HAI Solutions.
Prasad Sunkara, Ph. D has worked for Eyegenex, Inc., (Www.Eyegenex.Com), Peroral Biosciences, Inc., Seed To Fruit Ventures Llc, Semg Llc- Startup Express, and Hai Solutions.
You can use AeroLeads to view verified contact signals for Prasad Sunkara, Ph. D at HAI Solutions, including work email, phone, and LinkedIn data when available.
Prasad Sunkara, Ph. D holds Post Doctoral Fellowship, Cell And Tumor Biology from The University Of Texas Md Anderson Cancer Center Uthealth Graduate School Of Biomedical Sciences.
Prasad Sunkara, Ph. D is listed with skills including Biotechnology, Pharmaceutical Industry, Drug Discovery, Drug Development, Life Sciences, Clinical Development, Technology Transfer, and Lifesciences.
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial Search contacts